Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)?

M. Macerelli^*, C. Caramella, L. Faivre, B. Besse, D. Planchard, V. Polo, M. Ngo Camus, A. Celebic, V. Koubi-Pick, L. Lacroix, J. P. Pignon, J. C. Soria

^*Corresponding author for this work

Research output: Contribution to journal › Article › Research › peer-review